Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.

@article{Haschke2010UrinaryEO,
  title={Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.},
  author={Manuel Haschke and Tanja Vitins and Saskia L{\"u}de and Liliane Todesco and Kateřina Nov{\'a}kov{\'a} and Richard P Herrmann and Stephan Kr{\"a}henb{\"u}hl},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2010},
  volume={25 2},
  pages={
          426-33
        }
}
  • M. HaschkeTanja Vitins S. Krähenbühl
  • Published 1 February 2010
  • Medicine, Biology
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
BACKGROUND Patients treated with cisplatin or carboplatin show increased renal excretion of carnitine. It is currently unclear whether this is also the case for oxaliplatin and which are the responsible mechanisms. METHODS We investigated 22 patients treated either with a single dose of cisplatin, carboplatin or oxaliplatin. Carnitine and kidney function parameters were determined in plasma and urine. Inhibition and mRNA expression of OCTN2, the principle carnitine transporter, were assessed… 

Figures and Tables from this paper

Clinical Cancer esearch cer Therapy : Preclinical latin-Induced Downregulation of OCTN 2 Affects R nitine Wasting

The study shows a pivotal role of Oct1 and Oct2 in cisplatin-related disturbances in carhomeostasis and postulates that this phenomenon is triggered by deactivation of peroxisome pronitine liferator activated receptor α and leads to deregulation of carnitine-shuttle genes.

Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting

Cisplatin did not directly inhibit the transport of carnitine by Octn2 but downregulated multiple target genes of the transcription factor peroxisome proliferator activated receptor α in the kidney of wild-type mice that were absent in Oct1/2(−/−) mice, suggesting that tubular transport of cisplatin is a prerequisite for this phenomenon.

Repeated Combined Chemotherapy with Cisplatin Lowers Carnitine Levels in Gastric Cancer Patients

Carnitine levels decreased during repeated chemotherapy in patients with gastric cancer, and they are associated with the nutritional status.

Potential nephroprotective effects of l-carnitine against drug-induced nephropathy: a review of literature

Introduction: Drug-induced nephrotoxicity (DIN) has been reported with a great number of medications and contributes to ∼ 20% of hospital admissions. l-carnitine owing to its antioxidant,

Inhibition of Gene Expression of Organic Cation/Carnitine Transporter and Antioxidant Enzymes in Oxazaphosphorines-Induced Acute Cardiomyopathic Rat Models

Interestingly, carnitine supplementation completely reversed the biochemical and gene expression changes-induced by oxazaphosphorines to the control values, except OCTN2 expression remained inhibited by IFO.

Role of carnitine in cancer chemotherapy-induced multiple organ toxicity.

  • M. Sayed-Ahmed
  • Biology, Medicine
    Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
  • 2010

Increased Urinary Excretion of Carnitine and Acylcarnitine by Mercuric Chloride Is Reversed by 2,3-Dimercapto-1-Propanesulfonic Acid in Rats

Administration of HgCl2 resulted in statistically significant and dose-dependent increase in the urinary excretion of FC, AC, and TC in rats, however, the ratio of urinary AC:FC was significantly decreased by HGCl2.

Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model

Carnitine deficiency and oxidative stress, secondary to Fanconi Syndrome, constitute risk factors and should be viewed as mechanisms during development of IFO-induced cardiotoxicity, and PLC supplementation completely reversed the biochemical changes-induced by IFO to the control values.

Carboplatin-induced Fanconi-like syndrome in rats: amelioration by pentoxifylline.

Metabolomics for the early detection of cisplatin-induced nephrotoxicity.

Results indicate that the abovementioned metabolites might be reliable biomarker candidates that would allow the earlier detection of cisplatin-induced nephrotoxicity and that metabolomics is a useful tool for discovering biomarkers that could be used to predict the side effects of cancer therapy.

References

SHOWING 1-10 OF 39 REFERENCES

Increased urinary excretion of carnitine in patients treated with cisplatin

Treatment with cisplatin is associated with a tenfold increase in renal carnitine excretion, most likely due to inhibition of carn itine reabsorption by the proximal tubule of the nephron.

Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment

Treatment with carboplatin was associated with a marked urinary loss of LC and ALC, most likely due to inhibition of carnitine reabsorption in the kidney, and plasma concentrations and urinary excretion of glucose, phosphate and urea nitrogen and creatinine clearance, however, were not affected bycarboplatin therapy, indicating no impaired kidney function.

Urinary protein and enzyme excretion as markers of tubular damage

The measurement of urinary excretion of tubular enzymes and microproteins may be clinically useful in several different kidney diseases both for diagnosis and prediction of fractional outcome.

Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance.

The increased clearance of acylcarnitine and excretion of large amounts of AIAC are proposed to be a response to chemotherapy and represent a loss of energy to the cancer patient.

Cisplatin Nephrotoxicity: A Review

Understanding the mechanisms of injury has led to multiple approaches to prevention and potential approaches to treatment and the experimental approaches in these studies with cisplatin are potentially applicable to other drugs causing renal dysfunction.

Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis.

In nonoliguric ATN, increased urinary excretion of cystatin C and alpha(1)-microglobulin may predict an unfavorable outcome, as reflected by the requirement for RRT.

Histopathological Study of Human Cisplatin Nephropathy

The kidneys of ten autopsy cases showing impaired renal function following cisplatin therapy with hydration were examined histologically and no correlation could be found between the concentration level of platinum in the kidney and impairment of renal function.

Comparative Adverse Effect Profiles of Platinum Drugs

Strong relationships between carboplatin renal clearance, glomerular filtration rate, area under the plasma concentration-time curve (AUC) of filterable platinum and severity of thrombocytopenia have prompted dose adjustment according to renal function.

Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family)

Results indicate that cisplatin is a relatively good substrate of hOCT1, hO CT2, and hMATE1, and oxaliplatin has the potential to play predominant roles in the tissue distribution and anticancer effects and/or adverse effects of platinum agent-based chemotherapy.

Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates

The pharmacokinetic model distinguished between active drug and their inactive (inert) metabolites in plasma and CSF.